Navigation Links
Cadence Pharmaceuticals' CEO Theodore Schroeder to Present at UBS 2007 Global Life Sciences Conference
Date:9/20/2007

SAN DIEGO, Sept. 20 /PRNewswire-FirstCall/ -- Cadence Pharmaceuticals, Inc. (Nasdaq: CADX), a biopharmaceutical company focused on in-licensing, developing and commercializing proprietary product candidates principally for use in the hospital setting, announced today that the company's President and CEO Theodore Schroeder will present the corporate overview on Thursday, September 27, 2007 at 11:30 am Eastern Time (8:30 am Pacific Time) during the UBS 2007 Global Life Sciences Conference in New York City.

The presentation will be simultaneously webcast and can be accessed on Cadence Pharmaceuticals' website at http://www.cadencepharm.com in the Investor Relations section. A replay of the webcast will be available approximately three hours following the live webcasts and will be archived for 30 days.

About Cadence Pharmaceuticals, Inc.

Cadence Pharmaceuticals is a biopharmaceutical company focused on in-licensing, developing and commercializing proprietary product candidates principally for use in the hospital setting. The company currently has two Phase III product candidates in development, including intravenous acetaminophen (IV acetaminophen) for the treatment of acute pain and fever, and Omigard(TM) (omiganan pentahydrochloride 1% aqueous gel) for the prevention of catheter-related infections. For more information about Cadence's pipeline, visit http://www.cadencepharm.com.

Cadence(TM) and Omigard(TM) are trademarks of Cadence Pharmaceuticals, Inc.

Contacts: William R. LaRue Anna Gralinska

SVP & Chief Financial Officer Director, Investor
'/>"/>

SOURCE Cadence Pharmaceuticals, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Deltanoid Pharmaceuticals begins phase II osteoporosis study
2. The Coming of Biotech Generic Pharmaceuticals
3. Amplification of genome-representative DNA from limited sources with GenomePlex WGA technology for use in genetic alterations studies
4. Wisconsin firms to present at Cleantech venture capital event
5. New Sonic Foundry search engine finds words, phrases in video presentations
6. Lone Wisconsin firm to present at InvestMidwest
7. Sonic Foundry creates search engine for 7,000 expert video presentations
8. InvestMidWest calls for business presentations
9. Wicab to present BrainPort at Boston conference
10. Three more Wisconsin firms to present at venture forum
11. Six Wisconsin firms to present at BIO Mid-America VentureForum
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/21/2014)... , Aug. 21, 2014  BioSpecifics Technologies Corp. ... developing first in class collagenase-based products marketed as ... in the U.S. and XIAPEX ® in ... from a randomized, double-blind Phase 2a study of ... edematous fibrosclerotic panniculopathy. The results showed that all ...
(Date:8/21/2014)... Hershey, PA & Rockville, MD (PRWEB) August 21, 2014 ... Inc. (ITI) is making progress in its development ... allergy to Japanese red cedar pollen. Phase IC studies ... to a real solution to hay fever. , The ... in over 35 million people in Japan. Mountain Cedar ...
(Date:8/21/2014)... Finnish-Swedish research group at the Institute for Molecular ... institutet, Stockholm, has developed a novel "man and ... This innovative diagnostic aid was described in ... The method is based on computer vision algorithms ... combined with visualization of only the diagnostically most ...
(Date:8/21/2014)... international research team including DESY scientists has observed tiny ... team reports in the journal Science that ... inside the nanodroplets. It is the first time that ... larger samples of what is known as superfluid helium, ... our best expectations," says Andrey Vilesov of the University ...
Breaking Biology Technology:BioSpecifics Technologies Corp. Announces Positive Data from Phase 2a Study of CCH for Treatment of Cellulite 2BioSpecifics Technologies Corp. Announces Positive Data from Phase 2a Study of CCH for Treatment of Cellulite 3BioSpecifics Technologies Corp. Announces Positive Data from Phase 2a Study of CCH for Treatment of Cellulite 4BioSpecifics Technologies Corp. Announces Positive Data from Phase 2a Study of CCH for Treatment of Cellulite 5Relief for Allergy Sufferers Finally in Sight: Immunomic Therapeutics Closes in on Treatment for Hay Fever in Japan, U.S. 2Relief for Allergy Sufferers Finally in Sight: Immunomic Therapeutics Closes in on Treatment for Hay Fever in Japan, U.S. 3Relief for Allergy Sufferers Finally in Sight: Immunomic Therapeutics Closes in on Treatment for Hay Fever in Japan, U.S. 4A novel 'man and machine' decision support system makes malaria diagnostics more effective 2Scientists observe quantum vortices in cold helium droplets 2
... China , May 18 /PRNewswire-Asia/ -- Ningbo ... was officially put into operation, successfully being used in ... steel slag as an absorbent,instead of lime or other ... of lime agents, the replacement reduces SO2 emissions by,more ...
... CLEVELAND, Ohio , May 18, 2010 Simbionix USA Corporation,the ... and the healthcare industry, is proud to,report that their ANGIO Mentor virtual ... Societies in April 2010 for,the training and certification of vascular ... , , ...
... ... with ultra-fine finishing capabilities , ... (PRWEB) -- The increased miniaturization of medical devices such as surgical instruments ... the integral items that have helped to facilitate the use of miniaturized medical devices ...
Cached Biology Technology:TAIJI Announces Official Operation of Its Sintering FGD Project for Tangshan 2Simbionix ANGIO Mentor Plays Important Role in Physician Training and Certification 2Ultra-Fine Metal Tubing Smoothes the Way for Miniaturized Medical Devices 2Ultra-Fine Metal Tubing Smoothes the Way for Miniaturized Medical Devices 3
(Date:8/20/2014)... in in this image of the Para and Mato ... most likely intentionally set in order to deforest the ... stand of trees where the land is thereafter converted ... of forestland to farms, ranches, or urban use. The ... the Amazon Rainforest in the middle of the image ...
(Date:8/20/2014)... the Oklahoma Medical Research Foundation a five-year, $14.5 million ... bacteria,s effects on humans. , For 10 years, ... studied the human immune response to anthrax bacteria as ... original funding came soon after anthrax-laced letters killed five ... attacks of Sept. 11, 2001. , The long-term ...
(Date:8/20/2014)... seawater signals a relaxing trip to the shore. But ... comes with an environmental hitch. When certain sunblock ingredients ... become toxic to some of the ocean,s tiniest inhabitants, ... animals. Their study appears in the ACS journal ... David Snchez-Quiles point out that other than staying indoors, ...
Breaking Biology News(10 mins):$14.5 million grant awarded to continue anthrax studies 2
... shows that prenatal health care professionals are concerned about ... providing effective counseling. Rates of excessive weight gain ... adverse health outcomes for mothers and children, have increased ... care providers agree that weight gain is an important ...
... Palo Alto, CATo engineer better, more productive crops ... look at how the sensor-laden membranes surrounding cells ... interact with the environment and neighboring cells to ... about how proteins interact with these protective structures. ...
... to three-dimensional puzzles, Rubik,s Cube pales in comparison with ... Gordon and collaborators Chuck DeMets of the University of ... in Pasadena, Calif., have just put the finishing touches ... of the relative movements of the interlocking tectonic plates ...
Cached Biology News:Prenatal health-care providers inconsistent in weight-gain counseling 2Cracking the plant-cell membrane code 2Tectonics: Precision is hallmark of 20-year study 2Tectonics: Precision is hallmark of 20-year study 3
... tube luminometer provides the sensitivity and versatility ... Advanced digital photon counting with selected photomultipliers ... spectral demands. Equipped with up to 2 ... for reporter gene assays as well as ...
... convenient, and efficient native protein concentration following ... spin column to make handling easy. The ... which were electro-eluted in their native condition. ... high binding capacity fo all pH values. ...
MAb to HLA, Class II-DR+DP Dry Ice: No Preservative: NaN3 Availability When Not in Inventory: 14-21 Business Days...
Cell Culture Flask, nontreated polystyrene...
Biology Products: